Related references
Note: Only part of the references are listed.Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases
Giulio Cavalli et al.
AUTOIMMUNITY REVIEWS (2021)
Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis
Manuela Pardeo et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee
Gabriella Giancane et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
Lianne Kearsley-Fleet et al.
RHEUMATOLOGY (2019)
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study
Nienke M. ter Haar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response
Antonio Vitale et al.
FRONTIERS IN PHARMACOLOGY (2019)
Testing the Model for Predicting Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis reply
Jessica Tibaldi et al.
JOURNAL OF RHEUMATOLOGY (2019)
Storm Warning: Lung Disease in Systemic Juvenile Idiopathic Arthritis
Peter A. Nigrovic
ARTHRITIS & RHEUMATOLOGY (2019)
Anakinra in children and adults with Still's disease
Sebastiaan J. Vastert et al.
RHEUMATOLOGY (2019)
Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis
Benedetta Saccomanno et al.
JOURNAL OF RHEUMATOLOGY (2019)
JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS RELATED PANCREATITIS: AN UNCOMMON MANIFESTATION OF A COMMON DISEASE
Anjani Gummadi et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
Alessandro Consolaro et al.
LANCET CHILD & ADOLESCENT HEALTH (2019)
Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis
Grant S. Schulert et al.
ARTHRITIS CARE & RESEARCH (2018)
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
Joost Swart et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Current and future perspectives in the management of juvenile idiopathic arthritis
Nicolino Ruperto et al.
LANCET CHILD & ADOLESCENT HEALTH (2018)
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
Nicolino Ruperto et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
Gerd Horneff et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
Arndt H. Brachat et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
Alexei A. Grom et al.
ARTHRITIS & RHEUMATOLOGY (2016)
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Angelo Ravelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Monocyte MicroRNA Expression in Active Systemic Juvenile Idiopathic Arthritis Implicates MicroRNA-125a-5p in Polarized Monocyte Phenotypes
Grant S. Schulert et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience
Manuela Pardeo et al.
JOURNAL OF RHEUMATOLOGY (2015)
Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab
Shumpei Yokota et al.
JOURNAL OF RHEUMATOLOGY (2015)
Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity
Nanguneri Nirmala et al.
PEDIATRIC RHEUMATOLOGY (2015)
Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis Results of a Prospective Cohort Study
Sebastiaan J. Vastert et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis A Multinational, Multicenter Study of 362 Patients
Francesca Minoia et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab
Angelo Ravelli et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis
Yukiko Kimura et al.
ARTHRITIS CARE & RESEARCH (2013)
Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6
Masaki Shimizu et al.
CYTOKINE (2012)
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Nicolino Ruperto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
Pierre Quartier et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
J. B. Galloway et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Anakinra as First-Line Disease-Modifying Therapy in Systemic Juvenile Idiopathic Arthritis Report of Forty-Six Patients From an International Multicenter Series
Peter A. Nigrovic et al.
ARTHRITIS AND RHEUMATISM (2011)
Juvenile idiopathic arthritis
Berent Prakken et al.
LANCET (2011)
Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients
Paivi M. Miettunen et al.
RHEUMATOLOGY (2011)
The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
James B. Galloway et al.
RHEUMATOLOGY (2011)
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study
Norman Ilowite et al.
CLINICAL RHEUMATOLOGY (2009)
A case of macrophage activation syndrome successfully treated with anakinra
Alison Kelly et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2008)
Juvenile idiopathic arthritis
Angelo Ravelli et al.
LANCET (2007)
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
A Ravelli et al.
JOURNAL OF PEDIATRICS (2005)
Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain
JC Packham et al.
RHEUMATOLOGY (2002)
Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders
S Sawhney et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2001)
Share Paper
